Krystal Biotech, Inc. (KRYS) · Nov 2, 2026 · Earnings
Beat — Diluted EPS $2.05 vs ~$1.8 consensus; revenue $127.3M vs ~$126M
Krystal Biotech earnings beat on rising VYJUVEK revenue, while a new $400 million buyback offsets slower enrollment in key pipeline trials.
Krystal is a profitable commercial-stage gene-therapy company using VYJUVEK cash flow to expand internationally and fund a growing pipeline of registrational programs. Its prior-quarter setup already emphasized rising VYJUVEK sales, a strong balance sheet, and multiple expected clinical readouts.
The quarter cleared the market’s bar. Revenue reached $127.3 million, up 30% year over year, versus published expectations around $126 million; diluted EPS was $2.05 versus roughly $1.8 expected. That makes this a genuine earnings beat, though not a business-model rewrite. Gross margin was 94%, and operating income rose sharply as SG&A declined despite continued pipeline investment.
| Q3 2026 | Q3 2025 | Consensus | |
|---|---|---|---|
| Product revenue (Financial Highlights) | $127.3M (+30%) | $97.8M | ~$126M |
| Gross margin (Business Update) | 94% | — | — |
| Diluted EPS (Income Statement) | $2.05 | $2.66 | ~$1.8 |
| Operating income (Income Statement) | $71.1M (+71.9%) | $41.4M | — |
| Net income (Income Statement) | $63.1M (-20.5%) | $79.4M | — |
VYJUVEK is still doing the heavy lifting. U.S. reimbursement approvals have passed 760, while Germany, France, and Japan are moving through commercial expansion and Italy is now expected to launch in early 2027. 〔0〕 The revenue trajectory supports the central story that the commercial product can finance the broader platform rather than the company needing to fund development through repeated capital raises.
The $400 million repurchase is a new capital-allocation signal, not just routine earnings housekeeping. The authorization is discretionary, has no expiration date, and does not require Krystal to buy any shares. It reinforces management’s confidence in cash generation, but its economic impact is not yet realized because timing and volume remain unspecified.
The pipeline update is constructive but less clean than the headline beat. HALITE-1 remains on track for interim data before year-end, while IOLITE’s last-patient visit moved to February 2027 and EMERALD-1 enrollment is progressing slower than initially expected, pushing top-line results into 2027. 〔1〕 That does not break the pipeline thesis, but it makes the timing of future clinical value more dependent on execution than the prior narrative suggested.
Bottom line: This is a modestly better-than-expected quarter with strong VYJUVEK execution and a meaningful new buyback. The story advances, but slower clinical enrollment and several 2027 readouts keep it from being a company-changing update.
HALITE-1 interim results, before year-end
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!